Development of cell-based models for fibrolamellar carcinoma

纤维板层癌细胞模型的开发

• 批准号: 10512452
• 负责人: KHASHAYAR VAKILI
• 金额: $ 25.72万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10512452
• 关键词: Animals; Biological Assay; Biology; CRISPR/Cas technology; Catalytic Domain; Cell Culture Techniques; Cell Density; Cell Line; Cell Nucleus; Cell model; Cell-Matrix Junction; Cells; Cellular biology; Chemistry; Child; Chimeric Proteins; Chromosome 19; Collection; Cyclic AMP-Dependent Protein Kinases; Development; Disease; Disease-Free Survival; Dose; Engineering; Event; Excision; Exons; Fibrolamellar Hepatocellular Carcinoma; Fluorescence-Activated Cell Sorting; Gene Fusion; Genes; Genetic; Goals; Guide RNA; Heat shock proteins; Human; Human Engineering; In Vitro; Institutes; Kinetics; Libraries; Liver; Luciferases; Malignant Childhood Neoplasm; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of liver; Measurement; Measures; Methods; Mitochondria; Modeling; Mus; Oncogenic; Operative Surgical Procedures; Organoids; Output; PRKACA gene; Patients; Pharmaceutical Preparations; Pharmacology; Prognosis; Proteins; Proteomics; Protocols documentation; Reaction; Recurrence; Regimen; Reporter; Reproducibility; Research Proposals; Role; Secondary to; Small Interfering RNA; Testing; Therapeutic; Therapeutic Agents; Time; Transcript; Transfection; Untranslated RNA; base; chemotherapeutic agent; cholangiocyte; clinical efficacy; fusion gene; high risk; high throughput screening; high-throughput drug screening; inhibitor; interest; knock-down; leukemia; luminescence; novel; overexpression; promoter; protein kinase A kinase; response; sarcoma; screening; small hairpin RNA; stem cells; therapeutic target; therapeutically effective; tool; transcriptome; transcriptome sequencing; transcriptomics; tumor; young adult

PROJECT SUMMARY Fibrolamellar carcinoma (FLC) is a liver malignancy, most commonly occurring in children or young adults that carries an exceptionally poor prognosis given minimal response to conventional chemotherapeutic agents. Patients who undergo complete surgical resection are at high risk of recurrence and most will succumb to their disease, as demonstrated by a 5-year event-free survival of less than 10%. The genetic driver in FLC was first described in 2014 as a deletion event in chromosome 19 resulting in the DNAJB1-PRKACA (DP) gene fusion. Although the exact mechanisms by which this fusion protein results in cancer are unclear at this time, studies have demonstrated that induction of this fusion gene in mice is sufficient for the development of FLC tumors, supporting its role as a cancer driver. The role of fusion genes in various other cancers such as leukemia and sarcoma have been described and approaches to target the responsible fusion proteins have demonstrated clinical efficacy. Therefore, the overarching goal of our proposal is to develop cell-based tools for therapeutic targeting of DP protein since such models are currently lacking. Our first aim will be to develop a high throughput drug screening cell-based model by further modifying a novel cell line (HEK-DP) developed in our lab. HEK-DP is a cell line created through CRISPR/Cas9 editing to engineer the DP gene fusion in HEK293T cells. We have previously performed extensive transcriptomic, proteomic, and mitochondrial dynamic studies on the HEK-DP cells. We plan to modify the HEK-DP cells into a luminescent reporter for the activity of DP protein based on LINC00473 promoter. LINC00473 is a long non-coding RNA that is upregulated in FLC tumors as well as the HEK-DP cells. Our studies demonstrate that DP activity directly regulates LINC00473 expression in the HEK-DP cells and therefore, we anticipate that developing this reporter cell line will provide a novel tool for high throughput screening of drugs that can target DP activity. Our second aim will focus on editing human-derived liver progenitor cells to express DP fusion gene (Chol-Org-DP) using a similar strategy to HEK-DP engineering. Since the FLC cell origin is similar to the liver progenitor cells, the Chol-Org-DP cells will provide us with a powerful novel cell model to study the oncogenic mechanisms of DP as well as therapeutic screening.

项目总结 纤维板层癌(FLC)是一种肝脏恶性肿瘤，最常见于儿童或年轻人， 由于对常规化疗药物的反应极小，预后极差。 接受完全手术切除的患者复发的风险很高，而且大多数人会死于 疾病，如5年无事件生存率不到10%所证明的那样。FLC的遗传驱动因素是第一个 2014年被描述为19号染色体上的一次缺失事件，导致DNAJB1-PRKACA(DP)基因融合。 尽管目前这种融合蛋白导致癌症的确切机制尚不清楚，但研究 已经证明，在小鼠中诱导这种融合基因足以发展成FLC肿瘤， 支持其作为癌症推动者的角色。融合基因在白血病和其他多种癌症中的作用 肉瘤已被描述，靶向相关融合蛋白的方法已被证明。 临床疗效。因此，我们建议的首要目标是开发基于细胞的治疗工具 靶向DP蛋白，因为目前缺乏这样的模型。我们的首要目标将是开发一种高 基于细胞模型的药物筛选模型的进一步改进 实验室。HEK-DP是通过CRISPR/Cas9编辑获得的一株细胞株，用于在HEK293T中实现DP基因的融合 细胞。我们之前已经进行了广泛的转录、蛋白质组学和线粒体动力学研究 在HEK-DP细胞上。我们计划将HEK-DP细胞修饰成DP活性的发光报告 基于LINC00473启动子的蛋白质。LINC00473是一种在FLC中上调的长非编码RNA 肿瘤以及HEK-DP细胞。我们的研究表明，DP活性直接调节LINC00473 在HEK-DP细胞中表达，因此我们预计发展这种报告细胞系将提供一种 用于高通量筛选靶向DP活性的药物的新工具。我们的第二个目标将集中在 使用类似策略编辑人源性肝祖细胞以表达DP融合基因(Chol-Org-DP) 到HEK-DP工程。由于FLC细胞的来源与肝脏前体细胞相似，因此Chol-Org-DP细胞 将为我们研究DP的致癌机制提供一个强有力的新的细胞模型 治疗性筛查。